Table 2.
Adjusted Overall Survival, Female Patients with Inflammatory Breast Cancer, National Cancer Data Base, 2010–2014a
| cN0 (n=471, events=130) | cN1 (n=1506, events=431) | cN2–3 (n=820, events=295) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-Value | Overall P-Value | HR (95% CI) | P-Value | Overall P-Value | HR (95% CI) | P-Value | Overall P-Value | |
| Age | |||||||||
| Continuous | 1.02 (1.01 – 1.04) | 0.01 | 0.01 | 1.00 (1.00 – 1.01) | 0.27 | 0.27 | 1.00 (0.99 – 1.02) | 0.45 | 0.45 |
| Tumor Response | |||||||||
| ypN+ | -REF- | <0.001 | -REF- | <0.001 | -REF- | <0.001 | |||
| ypN0 | 0.32 (0.21 – 0.49) | <0.001 | - | 0.37 (0.28 – 0.47) | <0.001 | 0.37 (0.25 – 0.54) | <0.001 | ||
| # LNs examined | |||||||||
| ≤9 | -REF- | 0.83 | -REF- | 0.08 | -REF- | 0.06 | |||
| ≥10 | 0.96 (0.68 – 1.37) | 0.83 | 0.83 (0.68 – 1.02) | 0.08 | 0.78 (0.60 – 1.01) | 0.06 | |||
| Race/Ethnicityb | |||||||||
| Non-Hispanic White | - | - | - | -REF- | <0.001 | -REF- | 0.07 | ||
| Hispanic | - | - | - | 0.74 (0.47 – 1.17) | 0.19 | 0.79 (0.48 – 1.3) | 0.35 | ||
| Non-Hispanic Black | - | - | - | 1.51 (1.16 – 1.96) | 0.002 | 1.32 (0.98 – 1.77) | 0.06 | ||
| Non-Hispanic Other | - | - | - | 0.47 (0.17 – 1.34) | 0.16 | 0.53 (0.18 – 1.57) | 0.25 | ||
| Receptor Subtype | |||||||||
| HR+/HER2− | -REF- | 0.001 | -REF- | <0.001 | -REF- | <0.001 | |||
| HR+/HER2+ | 0.84 (0.48 – 1.50) | 0.56 | 0.88 (0.63 – 1.21) | 0.43 | 0.55 (0.35 – 0.86) | 0.01 | |||
| HR−/HER2+ | 1.26 (0.72 – 2.21) | 0.42 | 1.10 (0.78 – 1.55) | 0.59 | 0.76 (0.51 – 1.13) | 0.18 | |||
| TNBC | 2.17 (1.40 – 3.36) | <0.001 | 2.93 (2.32 – 3.70) | <0.001 | 2.60 (1.95 – 3.45) | <0.001 | |||
| Radiation | |||||||||
| No | -REF- | 0.50 | -REF- | <0.001 | -REF- | 0.03 | |||
| Yes | 0.86 (0.55 – 1.34) | 0.50 | 0.49 (0.38 – 0.64) | <0.001 | 0.69 (0.49 – 0.97) | 0.03 | |||
a
Patients diagnosed in 2015 were excluded from survival analyses due to insufficient follow-up and as recommended by the NCDB.
b
Race/Ethnicity not included in cN0 model to avoid overfitting given limited number of events. LN, lymph node. NACT, neoadjuvant chemotherapy. ypN+, ypN1–3 (i.e., persistent nodal disease). Interaction for LNs examined*nodal response (ypN0 vs ypN+) was non-significant for all 3 nodal groups: cN0 (p=0.69), cN1 (p=0.07), and cN2–3 (p=0.10). Interaction for Radiation*nodal response (ypN0 vs ypN+) was non-significant for all 3 nodal groups: cN0 (p=0.56), cN1 (p=0.24), and cN2–3 (p=0.88).